BOH (drug)
BOH, also known as 3,4-methylenedioxy-β-methoxyphenethylamine or as β-methoxy-MDPEA, is a drug of the phenethylamine, MDxx, and BOx families. It is the β-methoxy analogue of 3,4-methylenedioxyphenethylamine and is also more distantly related to methylone.
Use and effects
In his book PiHKAL, Alexander Shulgin lists BOH's dose range as 80 to 120mg orally and its duration as 6 to 8hours. The effects of BOH were reported to include distinct body awareness, a faint sense of inner warmth, mild mood enhancement, pupil dilation, skin prickling, bodily discomfort, loose bowels, decreased appetite, thirstiness, vague nausea, and cold feet. There were no clear psychedelic, entactogenic, or euphoriant effects described.
Pharmacology
Pharmacodynamics
On account of its structural similarity to norepinephrine, BOH might be purely adrenergic in nature.
Chemistry
Synthesis
The chemical synthesis of BOH has been described.
Analogues
Analogues of BOH include 3,4-methylenedioxyphenethylamine, 3C-BOH, BOB, BOD, and methylone, among others.
History
BOH was first described in the scientific literature by Alexander Shulgin, Peyton Jacob III, and Darrell Lemaire in 1985. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL.
Legal status
Canada
BOH is a controlled substance in Canada under phenethylamine blanket-ban language.
United Kingdom
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.
BOH is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.